Recent Updates — ACTU

The Nasdaq Stock Market LLC notified Actuate Therapeutics, Inc. that its common stock closed below the $1.00 per share minimum bid price for 30 consecutive business days. The company has an initial compliance period of 180 calendar days, ending April 26, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. Failure to comply may result in delisting or transfer to the Nasdaq Capital Market. This notice is separate from a prior deficiency regarding minimum market value requirements. Actuate Therapeutics operates in the biotechnology industry, focusing on drug discovery and development.

Actuate Therapeutics closed an underwritten public offering of 30,985,900 shares of common stock accompanied by warrants to purchase up to 15,492,950 additional shares. The securities were priced at $0.71 per unit, consisting of two shares and one warrant. Net proceeds totaled approximately $9.96 million after deducting underwriting discounts and offering expenses. The warrants carry an exercise price of $0.45 per share and expire five years from issuance. The company intends to use the net proceeds for working capital and general corporate purposes.

Actuate Therapeutics, Inc. received a notice from Nasdaq regarding its failure to meet the minimum Market Value of Listed Securities (MVLS) requirement of $50 million. The company has until January 11, 2027, to regain compliance with the MVLS requirement to avoid potential delisting from the Nasdaq Global Market. Actuate Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions.